Drug intelligence / Profile preview

flusalazine

Development stage: Preclinical
Lead developer: GNT Pharma
Modality: Small Molecules
Administration: Oral

Overview

Flusalazine is a small molecule drug candidate being developed by GNT Pharma for the treatment of inflammatory diseases, respiratory disorders (such as asthma and COPD), and pain. It is part of GNT Pharma's pipeline of multi-target anti-inflammatory compounds. While specific molecular targets have not been disclosed in detail, the drug is designed to address complex inflammatory pathways and oxidative stress, potentially acting as a next-generation derivative of the aminosalicylate class. It is currently in the early stages of development.

Targets

GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)PTGES (Microsomal prostaglandin E synthase-1)

Beyond the preview

Go deeper on flusalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on flusalazine.

Explore the full profile